FDA Not Following Up On Follow-On, Sandoz Says

FDA has not yet communicated to Sandoz any timeline for completing market authorization for the follow-on biologic Omnitrope (recombinant human growth hormone), in spite of a federal judge's ruling stipulating the agency make a decision